About Repligen
Repligen (NASDAQ:RGEN) specializes in the development, production, and commercialization of innovative bioprocessing technologies and solutions that significantly enhance the efficiency and flexibility of manufacturing processes in the biopharmaceutical industry. The company's portfolio includes products integral to the production of biological drugs, such as filtration and chromatography products, process analytics, and Protein A ligands. Repligen's mission is to collaborate closely with its clients to support the acceleration of drugs to market, focusing on improving the productivity and cost-effectiveness of biomanufacturing. With a strong commitment to quality and innovation, Repligen aims to expand its global footprint and continue delivering cutting-edge solutions that meet the evolving needs of the biopharmaceutical sector.
Snapshot
Operations
Products and/or services of Repligen
- Chromatography systems and columns for purifying biological drugs, ensuring high purity and efficacy.
- Filtration products, including tangential flow filtration and flat sheet filters, for bioprocessing applications.
- Protein A ligands, central to monoclonal antibody production, enhancing yield and purity.
- Cell culture growth factors, optimizing cell line development and biomanufacturing processes.
- Pre-packed columns and resins, offering convenience and reliability for downstream processing.
- Single-use assemblies, streamlining manufacturing workflows and reducing contamination risks.
Repligen executive team
- Mr. Anthony J. HuntExecutive Chair
- Mr. Olivier LoeillotPresident, CEO & Director
- Mr. Jason K. GarlandCFO & Chief Compliance Officer
- Mr. James R. BylundChief Operating Officer
- Mr. Ralf KuriyelSenior Vice President of Research & Development
- Ms. Violetta HughesChief Accounting Officer
- Mr. Michael MartinoChief Information Officer
- Mr. Jacob K. Johnson C.F.A.Vice President of Investor Relations
- Mr. George A. ScottSenior VP & General Counsel
- Mr. Neil WhitfieldSenior Vice President of Sales